CBRE vs PRME · P/E 43, rev $21.75B vs rev $4.6M
CBRE Group Inc Class A (CBRE) versus Prime Medicine, Inc. Common Stock (PRME) — a side-by-side from cached financials, not a winner call.
CBRE Group Inc Class A (CBRE) is a real estate services company listed on US.
Prime Medicine, Inc. Common Stock (PRME) is a biotechnology company listed on NASDAQ.
Latest reported CBRE revenue for 2026-06-30 was $21.75B. Net income was $522.0M. CBRE currently screens at market cap $41.66B and trailing P/E 42.7.
Latest reported PRME revenue for 2025-12-31 was $4.6M. Net income was -$201.1M. Revenue was up 55.3% from 2024-12-31 to 2025-12-31. PRME currently screens at market cap $570.8M.
CBRE currently screens at market cap $41.66B and trailing P/E 42.7. PRME currently screens at market cap $570.8M.
Not investment advice. Open the CBRE and PRME stock pages for the full models.
Not investment advice.